Skip to Main Content

Author Details

Kevin Punie
Leuven Cancer Institute and University Hospitals Leuven
2015
88
19
PMIDPaper TitleJournal TitlePublished Year
37878152Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.Breast Cancer Res Treat2024
37632634Serum methylmalonic acid concentrations at breast cancer diagnosis significantly correlate with clinical frailty.Geroscience2024
38059899Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study.JAMA2024
36379186Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.Eur J Cancer2023
38086864Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.Nat Commun2023
37919269Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.Nat Commun2023
37759086Circulating biomarkers at diagnosis correlate with distant metastases of early luminal-like breast cancer.Genes Immun2023
37659290Young oncologists' perspective on the role and future of the clinician-scientist in oncology.ESMO Open2023
37479706Obesity-associated changes in molecular biology of primary breast cancer.Nat Commun2023
37573673Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer.Eur J Cancer2023
37285719COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases.ESMO Open2023
37247580Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer.Eur J Cancer2023
37305385Targeting triple-negative breast cancer: A clinical perspective.Oncol Res2023
36473447Career and Professional Development for Young Oncologists.Oncol Res Treat2023
36739824Germline TP53 pathogenic variants and breast cancer: A narrative review.Cancer Treat Rev2023
36529568Corrigendum to "Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer": [Annals of Oncology 33 (2022) 769-785].Ann Oncol2023
35867203Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis.J Cancer Res Clin Oncol2023
35240902Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.Expert Opin Investig Drugs2022
35680967Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis.NPJ Breast Cancer2022
35769009Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets.Clin Chem2022
35545724Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.Breast Cancer Res Treat2022
35668001Elevated CA 15.3 in Newly Diagnosed Breast Cancer: A Retrospective Study.Clin Breast Cancer2022
35605746Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.Ann Oncol2022
36577919Correlation of TROP-2 expression with clinical-pathological characteristics and outcome in triple-negative breast cancer.Sci Rep2022
35970014PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment.ESMO Open2022
35998514Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?Cancer Treat Rev2022
36038616Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.NPJ Breast Cancer2022
36356416Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future.ESMO Open2022
36127427Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast.Nat Commun2022
36219936Impact of baseline telomere length on survival and chemotherapy related toxicity in breast cancer patients receiving (neo)adjuvant anthracycline containing chemotherapy.Transl Oncol2022
34861375Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate.Ann Oncol2022
34982322Preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer.Breast Cancer Res Treat2022
35007996The impact of COVID-19 on oncology professionals-one year on: lessons learned from the ESMO Resilience Task Force survey series.ESMO Open2022
32980945Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer.Breast Cancer Res Treat2021
33882206Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.N Engl J Med2021
33601295The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration.ESMO Open2021
33740501Immune-related adverse events after a single dose of pembrolizumab.Eur J Cancer2021
33763756Emerging Therapeutics for Patients with Triple-Negative Breast Cancer.Curr Oncol Rep2021
33822643OncoAlert Round Table Discussions: The Global COVID-19 Experience.JCO Glob Oncol2021
33558657Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2- early breast cancer.Mod Pathol2021
33579978Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants.NPJ Breast Cancer2021
34556657Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer.NPJ Breast Cancer2021
34611289Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis.Sci Rep2021
34775302Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer.ESMO Open2021
34449592Multitumor Case Series of Germline <i>BRCA1</i>, <i>BRCA2</i> and <i>CHEK2</i>-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors.Curr Oncol2021
34043927Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics.Expert Opin Biol Ther2021
34273808Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study.ESMO Open2021
33990587Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.Nat Commun2021
34217129The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II.ESMO Open2021
34271308Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3.ESMO Open2021
  • 1 - 50 of 88

Recommended Authors

Chiara Corti
University of Milano
Career Start Year 2017
Number of shared co-authors 4
Felipe Batalini
Mayo Clinic Arizona
Career Start Year 2015
Number of shared co-authors 4
Padma S Rajagopal
National Cancer Institute, National Institutes of Health
Career Start Year 2014
Number of shared co-authors 2
Martin Sj??str??m
University of California-San Francisco
Career Start Year 2013
Number of shared co-authors 1
Yin Liu
Fudan University Shanghai Cancer Center
Career Start Year 2011
Number of shared co-authors 0
Bo Gao
Crown Princess Mary Cancer Centre, Westmead Hospital
Career Start Year 2008
Number of shared co-authors 21
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 16
Julia A Beaver
Center for Drug Evaluation and Research
Career Start Year 2007
Number of shared co-authors 5
Bora Lim
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 1
Sharon F McGee
The Ottawa Hospital Cancer Centre
Career Start Year 2006
Number of shared co-authors 0
Christina Yau
University of California San Francisco
Career Start Year 2005
Number of shared co-authors 11
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 7
Nicola Fusco
IEO European Institute of Oncology IRCCS
Career Start Year 2002
Number of shared co-authors 3
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 13
Matthew P Goetz
Mayo Clinic
Career Start Year 2002
Number of shared co-authors 21
Richard B Schwab
Department of Medicine and Moores Cancer Center, University of California San Diego
Career Start Year 2000
Number of shared co-authors 3
Massimo Cristofanilli
Weill Cornell School of Medicine
Career Start Year 1998
Number of shared co-authors 12
Eleni Andreopoulou
New York Presbyterian Hospital
Career Start Year 1997
Number of shared co-authors 4
Carolien P Schr??der
University of Groningen, University Medical Center Groningen
Career Start Year 1995
Number of shared co-authors 31
Naoto T Ueno
Cancer Research Center of Hawaii: University of Hawai'i Cancer Center.
Career Start Year 1995
Number of shared co-authors 15
Steven J Isakoff
Massachusetts General Hospital
Career Start Year 1995
Number of shared co-authors 10
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 9
Daniel Rea
Institute of Cancer and Genomic Sciences, The University of Birmingham
Career Start Year 1993
Number of shared co-authors 10
Ramona F Swaby
Merck & Co., Inc.
Career Start Year 1991
Number of shared co-authors 5
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 15
Joan Albanell
Hospital del Mar Research Institute
Career Start Year 1990
Number of shared co-authors 10
Caroline Seynaeve
Erasmus Medical Center
Career Start Year 1990
Number of shared co-authors 59
Alberto Zambelli
IRCCS Humanitas Research Hospital
Career Start Year 1987
Number of shared co-authors 11
Gottfried E Konecny
David Geffen School of Medicine at University of California Los Angeles
Career Start Year 1984
Number of shared co-authors 35
Larry Norton
Memorial Sloan Kettering Cancer Center
Career Start Year 1976
Number of shared co-authors 19

Collaborators

Sara M Tolaney
Dana-Farber Cancer Institute
Co-authored papers 6
Diether Lambrechts
Co-authored papers 6
Aditya Bardia
Massachusetts General Hospital Cancer Center
Co-authored papers 6
Lisa A Carey
Co-authored papers 5
Rudolf Kaaks
Co-authored papers 4
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 4
Graham G Giles
Co-authored papers 4
Jenny Chang-Claude
German Cancer Research Center (DKFZ)
Co-authored papers 4
Peter A Fasching
Otto-Friedrich-University Bamberg
Co-authored papers 3
Roger L Milne
Co-authored papers 3
Paolo Radice
Ospedale Circolo e Fondazione Macchi
Co-authored papers 3
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Co-authored papers 3
Peter Kraft
Harvard T. H. Chan School of Public Health
Co-authored papers 3
Montserrat Garcia-Closas
National Cancer Institute
Co-authored papers 3
Giuseppe Curigliano
University of Milan
Co-authored papers 3
Christopher G Scott
Mayo Clinic
Co-authored papers 3
Alison M Dunning
Co-authored papers 3
Georgia Chenevix-Trench
QIMR Berghofer Medical Research Institute
Co-authored papers 3
Irene L Andrulis
University of Toronto
Co-authored papers 3
Christos Sotiriou
Co-authored papers 3
Douglas F Easton
University of Cambridge
Co-authored papers 3
Fergus J Couch
Mayo Clinic
Co-authored papers 3
Per Hall
Co-authored papers 3
Susana Banerjee
The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
Co-authored papers 3
Esther M John
Co-authored papers 3
Stephen J Chanock
National Cancer Institute, National Institutes of Health
Co-authored papers 3
Loic Le Marchand
Co-authored papers 3
Hoda Anton-Culver
University of California irvine
Co-authored papers 3
Christopher A Haiman
University of Southern California
Co-authored papers 3
Jonathan Beesley
QIMR Berghofer Medical Research Institute
Co-authored papers 3
Release 1.2